Otitis media (OM), or middle ear infection, is a highly prevalent pediatric disease worldwide. It ranks first in reasons why children visit physician's offices and emergency departments, undergo surgery under general anesthesia, and experience hearing loss. Three bacterial species predominate in OM, however due to broad use of capsular conjugate vaccines for Streptococcus pneumoniae (Spn), the microbiology of OM has shifted worldwide, with the relative proportion of cases due to nontypeable Haemophilus influenzae (NTHI) increasing significantly. NTHI are now considered equivalent to Spn as a causative agent of acute OM, yet remain the predominant pathogen of chronic OM and recurrent OM. There is thus a pressing need to develop better methods to manage NTHI-induced OM, preferably via development of vaccines to prevent it. To do so requires a complete understanding of the pathogenesis of disease and precise definition of the immunological target(s) that NTHI present. It is thus important to delineate the role of NTHI phase variation in pathobiology, including adherence, colonization of the nasopharynx (NP), biofilm formation, resistance to effectors of innate and acquired immunity and frequency/severity of induced OM. To date, using both multiple pediatric strain collections and a chinchilla model, we've shown that the NTHI ModA2 phasevarion is active as NTHI transition from benign colonization of the NP to overt infection of the middle ear and further, that it plays a major role in pathogenesis of experimental OM and altered expression of surface/vaccine antigens. Despite these intriguing observations, there remain multiple gaps in our understanding of NTHI phasevarions, the impact of epigenetic changes on pathogenesis, and the effect of phasevarion-mediated regulation of gene expression on selection of optimal vaccine candidates. Thereby, we propose two highly complementary and integrated specific aims to fill these gaps.
In Specific Aim 1, strong preliminary data on differential gene regulation in modA2, 4, 5, 9 & 10 phasevarions will support the conduct of a series of in vitro studies designed to probe the known niche-specific conditions that combine with phasevarion-mediated methylation changes to alter gene expression in NTHI.
Aim 1 studies are designed to deconstruct the multifactorial in vivo environment in order to individually characterize key biological selective pressures that act on phasevarion switching.
In Specific Aim 2, studies of modA4, 5, 9 & 10 ON and OFF variants will be conducted in a chinchilla model of OM to test the hypothesis that the observed phasevarion-mediated global changes in gene expression will provide a selective advantage in terms of niche adaptation in vivo.
Aim 2 studies are designed to characterize the full complement of biological selective pressures that act on phasevarion switching in concert, within the mammalian host. Findings derived from Aim 1 studies will be validated in Aim 2 by comparison with expression profile analysis of key genes using samples archived from niche adaptation studies and via direct testing in the chinchilla model using NTHI reporter constructs combined with ex vivo imaging to monitor niche-specific gene expression.
Each year, approximately 20 million physician's office visits are made, greater than 13 million antibiotic prescriptions are written, and $3-5 billion dollars are spent on medical and surgical management of childhood middle ear infections (or otitis media, OM) in the United States alone. Moreover, worldwide, between 65 and 330 million children suffer from chronic secretory OM which is characterized by ears that chronically drain pus through perforated ear drums; sixty percent of these children will experience an associated hearing loss in addition to a profoundly diminished quality of life. The most cost-effective way to manage this highly prevalent pediatric disease, and have a transformational effect on the health and lives of children worldwide, is through the development of both more effective therapeutic strategies and novel vaccines, a process which absolutely requires a thorough understanding of how the bacteria involved (particularly nontypeable Haemophilus influenzae) induce intractable chronic and/or recurrent disease ? gaining this comprehensive understanding is the long-term goal of the collaborative research program of the Bakaletz and Jennings laboratories.
|Apicella, Michael A; Coffin, Jeremy; Ketterer, Margaret et al. (2018) Nontypeable Haemophilus influenzae Lipooligosaccharide Expresses a Terminal Ketodeoxyoctanoate In Vivo, Which Can Be Used as a Target for Bactericidal Antibody. MBio 9:|
|Atack, John M; Day, Christopher J; Poole, Jessica et al. (2018) The HMW2 adhesin of non-typeable Haemophilus influenzae is a human-adapted lectin that mediates high-affinity binding to 2-6 linked N-acetylneuraminic acid glycans. Biochem Biophys Res Commun 503:1103-1107|
|Brockman, Kenneth L; Azzari, Patrick N; Branstool, M Taylor et al. (2018) Epigenetic Regulation Alters Biofilm Architecture and Composition in Multiple Clinical Isolates of Nontypeable Haemophilus influenzae. MBio 9:|
|Atack, John M; Tan, Aimee; Bakaletz, Lauren O et al. (2018) Phasevarions of Bacterial Pathogens: Methylomics Sheds New Light on Old Enemies. Trends Microbiol 26:715-726|
|Brockman, Kenneth L; Branstool, M Taylor; Atack, John M et al. (2017) The ModA2 Phasevarion of nontypeable Haemophilus influenzae Regulates Resistance to Oxidative Stress and Killing by Human Neutrophils. Sci Rep 7:3161|